| name | managing-infectious-disease-programs |
| description | Structures infectious disease control programs with prevention, testing, and treatment access protocols. Use when managing ID programs, implementing STI prevention, or coordinating TB control. |
| tags | ["management","public-health","treatment"] |
| metadata | {"author":"casemark","practice_areas":["Public Health","Epidemiology","Preventive Medicine"],"document_types":["Management Report"],"skill_modes":["Management","Coordination"]} |
Managing Infectious Disease Programs
Why This Skill Exists
Infectious disease programs are the operational core of communicable disease control at the state and local level. These programs span the full spectrum of prevention, detection, and response — from STI clinics and TB directly observed therapy (DOT) to HIV care continua and hepatitis elimination strategies. CDC funds these programs through multiple cooperative agreements: PS18-1802 (STI prevention), PS18-1802 (HIV prevention), PS20-2010 (TB elimination), and NU50CK000588 (ELC for emerging infections). Each program has disease-specific clinical guidelines (CDC STD Treatment Guidelines, ATS/CDC/IDSA TB guidelines, HHS HIV treatment guidelines), surveillance requirements (NNDSS, HIV Surveillance System, NTSS), and performance measures. The challenge is managing a portfolio of disease-specific programs under unified public health authority while maintaining the specialized clinical and operational expertise each disease demands. This skill structures that cross-cutting management framework.
Checkpoint A — Intake and Scoping
Intake Questions
- Which infectious diseases are in scope — STIs (chlamydia, gonorrhea, syphilis), HIV, TB, hepatitis B/C, vaccine-preventable diseases, foodborne/waterborne, healthcare-associated infections, or emerging infections?
- What CDC cooperative agreements fund the program(s)?
- What clinical services does the health department provide directly (STI clinic, TB clinic, HIV testing, immunizations)?
- What surveillance systems are in use (NNDSS, ELR, HIV Surveillance System/eHARS, NTSS, NEDSS)?
- What laboratory capacity exists — public health lab, commercial lab partnerships, antimicrobial susceptibility testing, molecular typing?
- What treatment access mechanisms are available — 340B drug pricing, ADAP (AIDS Drug Assistance Program), Ryan White, Medicaid, uninsured/underinsured programs?
- What is the jurisdiction's legal framework for partner notification, mandatory treatment, and quarantine?
- What linkage-to-care infrastructure exists — patient navigation, community health workers, care coordination?
Required Documents
- CDC cooperative agreement work plans and performance measures for each funded disease program
- Jurisdiction's list of reportable conditions with reporting timelines
- STD Treatment Guidelines (CDC, current edition)
- TB treatment guidelines (ATS/CDC/IDSA)
- HIV clinical guidelines (HHS, current edition)
- Surveillance annual reports for each disease program
- Disease investigation SOPs and interview protocols
- Laboratory services agreement with public health lab
- 340B and ADAP eligibility and coverage documentation
Step 1 — Maintain Surveillance and Data Systems
For each disease program, ensure surveillance infrastructure meets CDC requirements:
STI Surveillance:
- Case reporting: All cases of chlamydia, gonorrhea, syphilis (all stages), and chancroid are nationally notifiable. Ensure ELR feeds from all labs in the jurisdiction.
- Morbidity monitoring: Calculate rates per 100,000 by age, sex, race/ethnicity, and geography. Track trends against national NNDSS data and STD Surveillance Report.
- Congenital syphilis: Every reactive maternal syphilis serology must trigger a congenital syphilis evaluation per CDC case definition. Track congenital syphilis as a sentinel indicator of prevention system failure.
- Antimicrobial resistance: Participate in GISP (Gonococcal Isolate Surveillance Project) if the jurisdiction is a GISP site. Monitor local susceptibility patterns.
HIV Surveillance:
- Use eHARS (Enhanced HIV/AIDS Reporting System) for case reporting and management.
- Generate the HIV Care Continuum for the jurisdiction: diagnosed → linked to care (within 30 days) → retained in care → virally suppressed (< 200 copies/mL). Stratify by demographics.
- Report to CDC National HIV Surveillance System per quarterly and annual data submission schedules.
TB Surveillance:
- Report to the National TB Surveillance System (NTSS) via RVCT (Report of Verified Case of TB).
- Track treatment outcomes: completion rate target ≥ 93% for drug-susceptible TB.
- Monitor genotyping/WGS data for cluster detection indicating recent transmission.
Step 2 — Implement Prevention Programs
STI Prevention:
- Screening per USPSTF/CDC guidelines: annual chlamydia/gonorrhea screening for sexually active women < 25, syphilis screening for all pregnant women at first prenatal visit, risk-based screening for MSM (every 3-6 months for STIs including pharyngeal/rectal), and extragenital site testing.
- Partner services (DIS — Disease Intervention Specialists): For syphilis (all stages), HIV, and gonorrhea/chlamydia where capacity allows. DIS conduct case interviews, elicit partners, provide partner notification, and link to testing/treatment.
- Expedited partner therapy (EPT) for chlamydia and gonorrhea where state law permits.
- Doxy-PEP (doxycycline post-exposure prophylaxis): Implement per CDC 2023 guidelines for MSM and transgender women with recent STI, in partnership with HIV/STI clinical providers.
HIV Prevention:
- PrEP (pre-exposure prophylaxis): Expand PrEP access per the national EHE (Ending the HIV Epidemic) strategy. Track PrEP-to-Need Ratio (PNR) by demographics and geography.
- HIV testing: Implement routine opt-out testing in clinical settings (per CDC 2006 guidelines) and targeted testing in non-clinical settings (community-based testing, mobile units). Link all new positives to care within 72 hours.
- Syringe services programs (SSPs): Operate or fund SSPs per CDC guidelines — providing sterile syringes, naloxone, HIV/HCV testing, and referral to substance use treatment.
TB Prevention:
- Targeted testing and treatment of latent TB infection (LTBI) in high-risk populations: contacts of active TB cases, foreign-born persons from high-incidence countries, persons with HIV, immunosuppressed persons, healthcare workers.
- Short-course LTBI regimens preferred: 3HP (12-dose rifapentine + isoniazid weekly for 3 months) or 4R (4 months of rifampin).
Step 3 — Ensure Treatment Access and Clinical Quality
- STI treatment: Provide or ensure access to CDC-guideline-concordant treatment. For gonorrhea: ceftriaxone 500mg IM (1g if ≥ 150kg). For chlamydia: doxycycline 100mg BID × 7 days. For syphilis: benzathine penicillin G per staging. Ensure treatment availability at STI clinics, EDs, FQHCs, and through EPT.
- HIV treatment: Rapid ART initiation — same-day or next-day start for all new HIV diagnoses (per HHS guidelines). Linkage to Ryan White–funded care for uninsured/underinsured. Monitor viral suppression rates through surveillance.
- TB treatment: DOT (directly observed therapy) for all active TB cases. Standard 4-drug regimen (RIPE: rifampin, isoniazid, pyrazinamide, ethambutol) for drug-susceptible TB. Drug-resistant TB managed by or in consultation with a TB expert (CDR, state TB medical consultant, or CDC DTBE).
- Hepatitis C treatment: Screen per USPSTF (all adults 18-79), link positives to DAA (direct-acting antiviral) treatment. Partner with hepatitis elimination programs and 340B-participating providers.
- 340B program: Maximize 340B drug pricing for STI, HIV, and TB medications. Ensure program compliance with HRSA 340B requirements.
Step 4 — Manage Outbreaks and Clusters
- Implement outbreak response protocols for: syphilis clusters (especially congenital syphilis), HIV clusters (detected via molecular surveillance — related sequences within genetic distance threshold), TB genotype clusters, foodborne outbreaks, and healthcare-associated infection outbreaks.
- For HIV molecular clusters: use Secure HIV-TRACE or equivalent tool per CDC cluster detection and response guidance. Convene a rapid response team. Prioritize partner services, testing saturation, and PrEP/treatment linkage in the cluster network.
- For congenital syphilis: every case triggers a systems review — was the mother screened, was the positive identified and treated, was treatment adequate and timely? Identify and correct system failures.
- For TB clusters: assess for recent transmission using WGS data (0-5 SNP difference = likely recent transmission). Conduct expanded contact investigation and evaluate environmental contributors (congregate settings, poor ventilation).
Step 5 — Report and Evaluate Program Performance
- Submit required data to CDC surveillance systems on schedule: NNDSS weekly/annual, eHARS quarterly/annual, NTSS case reports within 90 days of case verification.
- Generate annual disease-specific surveillance reports with case counts, rates, trends, and demographic stratification.
- Report cooperative agreement performance measures per CDC program guidance.
- Evaluate program effectiveness using process and outcome measures:
- STI: screening rates, positivity rates, treatment timeliness, partner services index (contacts per case), EPT utilization, congenital syphilis rate.
- HIV: testing volume, new diagnosis rate, linkage-to-care timeliness, PrEP prescriptions, viral suppression rate, HIV care continuum gaps.
- TB: case count and rate, treatment completion rate, LTBI treatment initiation and completion rate, contact investigation yield.
Checkpoint B — Program Review
Quality Audit
Guidelines
- Confidentiality is paramount. Infectious disease data — especially HIV, STI, and TB — carries significant stigma. All data handling must comply with state confidentiality statutes, HIPAA, and CDC data security guidelines. Never release identifiable data without legal authority.
- Partner notification is a clinical and public health intervention, not a punitive action. DIS must be trained in motivational interviewing, trauma-informed care, and cultural humility. Coercive approaches undermine trust and reduce future cooperation.
- Antimicrobial resistance is an evolving threat. Gonorrhea treatment failures and rising MICs must be reported immediately to the state STD program and CDC DSTDP. Do not treat gonorrhea with regimens other than the current CDC-recommended first-line without susceptibility data.
- HIV molecular surveillance data must be protected with the highest security standards. This data can reveal transmission networks and is subject to misuse if accessed by law enforcement or immigration authorities. Follow CDC's June 2022 guidance on molecular HIV surveillance data use.
- Congenital syphilis is a preventable tragedy and a sentinel event. Every case represents a system failure — missed screening, missed diagnosis, inadequate treatment, or failed follow-up. Treat it as such in quality reviews.
- TB control depends on treatment completion. DOT is resource-intensive but remains the standard. VDOT (video-DOT) is an acceptable alternative per CDC guidance when it meets quality standards (direct observation of each dose, secure technology platform).
- Escalate to state epidemiologist or CDC program consultant when: antimicrobial-resistant gonorrhea is suspected, an HIV molecular cluster exceeds 5 new diagnoses in 12 months, a congenital syphilis cluster is identified, or a multidrug-resistant TB case is diagnosed.
